The timing of administration, dose dependence and efficacy of dopa decarboxylase inhibitors on the reversal of motor disability produced by L-DOPA in the MPTP-treated common marmoset.
Tayarani-Binazir
Kayhan A
KA
Neurodegenerative Diseases Research Centre, School of Health and Biomedical Sciences, King's College, London, UK.
Jackson
Michael J
MJ
Fisher
Ria
R
Zoubiane
Ghada
G
Rose
Sarah
S
Jenner
Peter
P
D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine / Q000494:pharmacology*; D000818:Animals; D065105:Aromatic Amino Acid Decarboxylase Inhibitors; D001545:Benserazide / Q000008:administration & dosage / Q000494:pharmacology; D002144:Callithrix; D002230:Carbidopa / Q000008:administration & dosage / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004357:Drug Synergism; D004791:Enzyme Inhibitors / Q000008:administration & dosage* / Q000494:pharmacology*; D005260:Female; D007980:Levodopa / Q000494:pharmacology* / Q000627:therapeutic use; D008297:Male; D008750:Methyldopa / Q000008:administration & dosage / Q000494:pharmacology; D009043:Motor Activity / Q000187:drug effects; D009069:Movement Disorders / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology
D065105:Aromatic Amino Acid Decarboxylase Inhibitors; D004791:Enzyme Inhibitors; D007980:Levodopa; D008750:Methyldopa; D001545:Benserazide; D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; D002230:Carbidopa